These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1179 related items for PubMed ID: 24662102

  • 1. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L.
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [Abstract] [Full Text] [Related]

  • 2. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J, Morgan S, Walker Z.
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.
    J Alzheimers Dis; 2013 Oct; 35(2):349-61. PubMed ID: 23411693
    [Abstract] [Full Text] [Related]

  • 6. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.
    Health Technol Assess; 2012 Oct; 16(21):1-470. PubMed ID: 22541366
    [Abstract] [Full Text] [Related]

  • 7. [Medical treatment of Alzheimer's disease].
    Johannsen P.
    Ugeskr Laeger; 2006 Oct 02; 168(40):3424-9. PubMed ID: 17032609
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S, Lanctôt KL, Herrmann N.
    Expert Opin Drug Saf; 2004 Sep 02; 3(5):425-40. PubMed ID: 15335298
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacologic management of Alzheimer disease.
    Downey D.
    J Neurosci Nurs; 2008 Feb 02; 40(1):55-9. PubMed ID: 18330411
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA.
    Am J Health Syst Pharm; 2009 May 15; 66(10):899-907. PubMed ID: 19420308
    [Abstract] [Full Text] [Related]

  • 15. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ.
    Cochrane Database Syst Rev; 2021 Feb 22; 2(2):CD013306. PubMed ID: 33704781
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.
    Health Technol Assess; 2006 Jan 22; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.